Given temporary inhibition of endocytosis using PCZ has been proposed for various clinical applications, including viral infections, chronic kidney disease, and cancer 56-59, blocking the CME pathway with PCZ to inhibit PLA2R endocytosis may disrupt the functional effects of PLA2R antibodies, offering a potential intervention strategy for PMN. The gene discussed is PLA2R1; the disease is chronic kidney disease.